Profile data is unavailable for this security.
About the company
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.
- Revenue in USD (TTM)21.25m
- Net income in USD-16.05m
- Incorporated2011
- Employees36.00
- LocationFennec Pharmaceuticals Inc68 Tw Alexander DrPO Box 13628RESEARCH TRIANGLE PARK 27709United StatesUSA
- Phone+1 (919) 636-4530
- Fax+1 (919) 890-0490
- Websitehttps://fennecpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiol Therapeutics Inc | 0.00 | -28.13m | 185.05m | 17.00 | -- | 6.27 | -- | -- | -0.4363 | -0.4363 | 0.00 | 0.4322 | 0.00 | -- | -- | -- | -56.98 | -58.97 | -69.77 | -68.62 | -- | -- | -- | -158,738.10 | -- | -- | 0.0061 | -- | -- | -- | 9.06 | -- | 36.06 | -- |
| Cipher Pharmaceuticals Inc | 28.96m | 27.89m | 215.76m | 6.00 | 8.22 | 1.95 | 7.30 | 7.45 | 1.09 | 1.09 | 1.13 | 4.59 | 0.2648 | 1.59 | 3.56 | -- | 25.51 | 21.53 | 28.08 | 27.40 | 80.77 | 83.58 | 96.32 | 57.31 | 8.62 | -- | 0.0044 | 0.00 | 2.36 | -1.44 | -23.48 | 76.18 | -53.51 | -- |
| OrganiGram Holdings Inc | 154.77m | -269.68m | 264.20m | 984.00 | -- | 0.8059 | -- | 1.71 | -3.37 | -3.37 | 1.89 | 3.18 | 0.3549 | 2.22 | 5.77 | 165,532.60 | -61.84 | -23.49 | -68.43 | -25.39 | -21.04 | -6.87 | -174.24 | -97.37 | 2.11 | -- | 0.0005 | -- | 10.86 | 67.04 | -1,640.54 | -- | -11.62 | -- |
| Fennec Pharmaceuticals Inc | 29.08m | -21.96m | 342.28m | 36.00 | -- | -- | -- | 11.77 | -0.8268 | -0.8268 | 1.09 | -0.5884 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Aurora Cannabis Inc | 266.97m | -125.07m | 501.76m | 1.13k | -- | 0.8478 | -- | 1.88 | -3.39 | -3.63 | 6.83 | 10.85 | 0.29 | 1.96 | 6.57 | 236,259.30 | -14.60 | -- | -17.65 | -- | 1.93 | -- | -50.34 | -- | 2.45 | -23.12 | 0.1562 | -- | -- | -- | -- | -- | -- | -- |
